Fount of Information

TriLink社 Beyond COVID-19: The Next Wave of Promising Applications for mRNA Vaccines

この製品に関するご照会・お問合せはこちら

logo.png

MESSENGER.png

 

RESEARCH NEWS

ZONE_IN_ZON.png

Beyond COVID-19: The Next Wave of Promising Applications for mRNA Vaccines


Influenza is one of the most common communicable diseases in the world. Annually, there are an estimated ~650,000 deaths worldwide attributed to the flu. Unfortunately, currently administered seasonal flu vaccines only demonstrate 10–60% efficacy, depending on the year. New mRNA flu vaccines can offer more effective next-generation replacements for current flu vaccine strategies. Learn more about the public health issues caused by viruses like influenza, as well as how mRNA vaccinology is providing promising solutions. 

 

READ_MORE.PNG

 

Lyme.png

A Novel mRNA Vaccine Induces Tick Resistance to Prevent Lyme Disease

Game_Changer.png

 mRNA: A Game Changer in Drug Development

 

Tick-borne diseases are increasing in the United States with the most common one, Lyme disease, resulting in around 40,000 cases annually. With the most recent success in using mRNA for coronavirus vaccines, researchers are now considering looking at that approach for tick-borne agents. Read more about the efficacy of mRNA vaccines to prevent Lyme disease in our latest Research Spotlight.​​​​

As 2021 comes to a close, we're reflecting on the leaps and bounds made in advancing mRNA-based vaccines and therapeutics for human use this year. In our final Research Spotlight of 2021, researchers review the intense efforts that shaped and optimized the technology, and highlight the future potential of mRNA as a true game changer!

 

READ_MORE.PNG READ_MORE.PNG

 

UPCOMING EVENTS

 

Mark_your_calendars.jpg

mRNA Based Therapeutic Summit - Virtual

The mRNA based Therapeutic Summit brings together key opinion leaders from Europe and the rest of the world to delve deep into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines & therapeutics with improved specificity, delivery & efficacy for immuno-oncology, infectious diseases, and beyond.

 

As part of this conference, our Sr. Business Development Manager (Europe), Alexandre Di Paolo, will do a short presentation about in vitro transcribed (IVT) mRNA.

 

Tuesday, January 25 - Thursday January 27, 2022 (CET)

Tuesday, January 25, 17:30 - Thursday January 28, 02:30, 2022 (JST)

 

REGISTER_NOW.PNG

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。